Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBIAT (2021 - 2025)

Kiniksa Pharmaceuticals International's EBIAT history spans 5 years, with the latest figure at $14.2 million for Q4 2025.

  • For Q4 2025, EBIAT rose 259.75% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $59.0 million, up 236.61%, while the annual FY2025 figure was $59.0 million, 236.61% up from the prior year.
  • EBIAT reached $14.2 million in Q4 2025 per KNSA's latest filing, down from $18.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $224.1 million in Q3 2022 to a low of -$49.5 million in Q1 2021.
  • Average EBIAT over 5 years is $2.8 million, with a median of -$10.6 million recorded in 2023.
  • Peak YoY movement for EBIAT: skyrocketed 833.67% in 2022, then plummeted 135.22% in 2024.
  • A 5-year view of EBIAT shows it stood at -$36.3 million in 2021, then surged by 112.28% to $4.5 million in 2022, then surged by 465.73% to $25.2 million in 2023, then crashed by 135.22% to -$8.9 million in 2024, then surged by 259.75% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EBIAT are $14.2 million (Q4 2025), $18.4 million (Q3 2025), and $17.8 million (Q2 2025).